Observational studyJournal of Crohn's & colitis2025
Kinetics of intestinal ultrasound and shear-wave elastography to assess early response in ulcerative colitis patients treated with filgotinib.
Observational study in Journal of Crohn's & colitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intestinal Ultrasound in Inflammatory Bowel Disease: Monitoring Inflammation and Treatment Response.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
aimsA reduction of bowel wall thickness (BWT) on intestinal ultrasound (IUS) predicts endoscopic response in ulcerative colitis (UC). Advanced techniques such as shear-wave elastography (SWE) might enhance response assessment. We aimed to identify early IUS parameters to predict treatment response to filgotinib in UC.
methodsThis prospective observational study included UC patients with endoscopically active disease (endoscopic Mayo score [EMS] ≥2, extending beyond the rectum) starting on filgotinib. IUS parameters, including SWE, were assessed at baseline (T0), week 4 (T1), and at second endoscopy (T2). EMS of both the most-affected segment and the sigmoid was assessed at T0 and T2, and endoscopic response was defined a ≥1 point decrease in EMS.
resultsA total of 23 patients were included. Six of 21 patients who underwent a second endoscopy were endoscopic responders. At T1 in the sigmoid, a BWT decrease of ≥1.33 mm or ≥24.7% (odds ratio [OR]: 32.5 [2.4-443.2], P = .009 and OR: 13.8 [1.2-156.6], P = .035) and submucosa decrease of ≥20.8% (OR: 13.8 [1.2-156.6], P = .035) predicted endoscopic response. Additionally, color Doppler signal (CDS) improvement at T1 predicted endoscopic response (OR: 20.0 [1.7-241.7], P = .018). In the sigmoid, SWE values changed differently over time between responders and non-responders (T2: 9.9 ± 15.7 vs -8.1 ± 11.4 kPa, P = .002). However, SWE values at T1 were not predictive of endoscopic response (OR: 1.07 [0.99-1.16], P = .088).
conclusionsOn IUS, BWT, submucosal thickness, and CDS predict endoscopic response after 4 weeks of filgotinib treatment. SWE values in the sigmoid differ between responders and non-responders, but early assessment does not predict treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.